Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease, Late Onset: early-phase trial registry
3 of 8 indexed Alzheimer Disease, Late Onset trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Alzheimer Disease, Late Onset: 8 US clinical trials tracked, 3 recruiting.
Alzheimer Disease, Late Onset is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is NeuroEM Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease-late-onset
OPEN 3 | RECR 38% | LATE 0 | EARLY 1 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Alzheimer Disease, Late Onset lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease, Late Onset on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease, Late Onset is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease, Late Onset trials is spread across many organizations.
NeuroEM Therapeutics accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease, Late Onset enrolment sits around 344 participants.
Median target enrolment is 344 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.
-
Alzheimer Disease, Late Onset splits between interventional and observational designs.
5 interventional and 3 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
NYSCF Scientific Discovery Biobank
New York Stem Cell Foundation Research Institute
NCT06203106
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
University of Pittsburgh
NCT05138848
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Massachusetts Institute of Technology
NCT05655195
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Cognito Therapeutics
NCT05637801
Reducing Risk of Dementia Through Deprescribing
Indiana University
NCT04270474
Genetic Studies in Familial Dementia
University of Miami
NCT04680013
Synaptic Injury and Functional Connectivity in Alzheimer's Disease
Ohio State University
NCT03300726
Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease
NeuroEM Therapeutics
NCT02958930
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease, Late Onset records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease, Late Onset trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease, Late Onset page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Alzheimer Disease, Late Onset trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NeuroEM Therapeutics sponsors the most Alzheimer Disease, Late Onset trials on record, review their full trial history before evaluating a specific study. See NeuroEM Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease, Late Onset condition card totals 8 registered trials; most-linked intervention MemorEM 1000; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.